XARELTO^®: Dosing for chronic peripheral artery disease (PAD) post lower extremity revascularization¹

Condition-Specific Dosing

2.5 mg

Twice daily with or without food in combination with aspirin (75 mg to 100 mg) once daily

When starting therapy after a successful LER procedure, initiate once hemostasis has been established

No dose adjustment needed based on CrCl

2.5 mg

Twice daily with or without food in combination with aspirin (75 mg to 100 mg) once daily

No dose adjustment needed based on CrCl

Renal Dosing Considerations

CAD and/or PAD: For patients with CrCl <15 mL/min, no data are available, and limited data are available for patients with a CrCl of 15 to 30 mL/min. Clinical efficacy and safety studies with XARELTO^® did not enroll patients with end-stage renal disease (ESRD) on dialysis.

Switch and Management

XARELTO^® Dosing: All Indications

CrCl = creatinine clearance; LER = lower extremity revascularization.

Previous: PAD Summary

XARELTO®: Dosing for chronic peripheral artery disease (PAD) post lower extremity revascularization1

Condition-Specific Dosing

PAD:Reducing the risk of major thrombotic vascular events, including in patients who have recently undergone an LER procedure due to symptomatic PAD

Chronic PAD:Reducing the risk of major thrombotic vascular events

XARELTO^®: Dosing for chronic peripheral artery disease (PAD) post lower extremity revascularization¹